At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 291 enrolled
Drug / intervention
Dulaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Dulaglutide, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 291 participants across 27 sites.
Detailed Summary
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionApr 2022
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartDec 7, 2020
Primary CompletionApr 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.7 years ago
Interventions
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC
Insulin Glarginedrug
Administered SC